ESALY
Get informed when a big investor buys or sells
+ Follow| Market cap | $17.64 Billion |
|---|---|
| Enterprise Value | $-100,246,837,944.00 |
| Dividend Yield | $19.23 (4.10%) |
| Earnings per Share | $159.44 |
| Beta | 0 |
| Outstanding Shares | 286,794,957 |
| P/E Ratio | 28.54 |
|---|---|
| PEG | -94.9 |
| Price to Sales | 0.02 |
| Price to Book Ratio | 0.02 |
| Enterprise Value to Revenue | -0.14 |
| Enterprise Value to EBIT | 64.47 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | -1.5 |
| Debt to Equity | 0.19 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Controls taxation, trade, and entitlement spending (like Medicare and Medicaid), directly impacting pharmaceutical company profitability through tax policy, market access, and drug reimbursement rates.
Directly controls the allocation of federal funds to agencies critical for the pharmaceutical industry, such as the NIH (research) and the FDA (regulation), and determines budgets for government drug procurement.
Directly regulates the FDA (responsible for drug approval and safety) and oversees the NIH (major funder of biomedical research), making it a primary legislative body for the pharmaceutical industry.
Has direct oversight over intellectual property (patents), which is fundamental to the pharmaceutical business model, and antitrust enforcement, which impacts mergers and acquisitions within the industry.